Effects of adding budesonide/formoterol in patients with COPD

Effects of adding budesonide/formoterol in patients with COPD - Effects of budesonide/formoterol

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008394

Enrollment

Registered

2012-07-10

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD)

Interventions

Inhaled budesonide/formoterol for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic obstructive pulmonary disease (COPD) Patients can use the inhaled therapy Patients gave written informed consent

Exclusion criteria

Exclusion criteria: History of hyper-sensitivity to budesonide/formoterol Patients with bronchial asthma Patients during acute exacerbation Presence of infectious disease, pneumothorax, and severe heart failure

Design outcomes

Primary

Measure	Time frame
Pulmonary function test	—

Secondary

Measure	Time frame
Imaging St. George's Respiratory Questionnaire (SGRQ)	—

Countries

Japan

Contacts

Public ContactHideki Yasui

Hamamatsu University School of Medicine Second Division, Department of Internal medicine

053-435-2263

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026